Impact of FDA Leadership and NIH Funding on Life Science Demand Q1 2026

Current life science demand challenges tied to FDA leadership uncertainty and NIH budget issues

Based on the provided earnings call excerpts from Alexandria Real Estate Equities (ARE), the “pinch points” affecting demand in the life science space right now include NIH-related funding uncertainty and FDA-related leadership/policy instability, both of which indirectly impact real-estate demand by increasing time, cost, and uncertainty about “approvability” for tenants’ R&D pipelines. ¹

---

1) NIH budget pressure and reimbursement policy friction are disrupting early-stage demand

A. NIH indirect cost reimbursement limitations created a demand pause

Management describes a “turmoil at NIH” that “impacted us directly in a number of markets,” and specifically references limitations on indirect cost reimbursement as part of the NIH-driven pressure that affected activity. ¹

B. Budget reduction pressure increases uncertainty for early-stage work

The excerpt also notes NIH “going to the hill wanting a reduction in their budget,” which management says is unusual because “Congress on both sides…are in favor of more or less fully funding the NIH.” ¹ This framing implies that NIH funding risk is not just a one-off reimbursement issue—it feeds broader uncertainty about the resources available for research programs.

C. Demand effects show up as halts and slowed leasing until policy stabilizes

A concrete example is given in the context of a specific asset (“NIH 15% kind of brought a halt to almost all demand, certainly in the Boston area and to some extent across the country”). ² Management then ties improvement to the policy being “overturned in the circuit courts,” but emphasizes it “will just take a little bit of time.” ²

Net effect on demand

Overall, NIH issues appear to affect demand most strongly where tenants’ projects are early-stage and more sensitive to research funding terms and institutional cost structures, creating pauses or delays in leasing/expansion decisions until reimbursement and budget outlooks become more predictable. ¹²

---

2) FDA leadership and policy uncertainty is described as a frequent “shock effect” on pipeline timelines and approvability

A. Leadership uncertainty + frequent adverse regulatory signals increase timeline and cost risk

Management explicitly calls “FDA” a “huge problem,” noting “almost every day” there are releases that create uncertainty, including a cited example where the FDA “may try to pull an approved drug off the market” due to alleged data manipulation. ¹

They characterize this as a “shock effect” from the FDA “both at the leadership and at the core level.” ¹

B. The key mechanism: tenants must manage time, cost, and approvability

Management links FDA uncertainty to tenant decision-making fundamentals: when “thinking about funding, whether it’s preclinical or into the clinic,” companies must be “mindful of time, cost and approvability.” ¹ In other words, FDA instability raises the risk-adjusted cost of progressing programs, which can slow or reduce the willingness to expand facilities.

C. Regulatory policy is not reliably translating into faster outcomes

A related excerpt acknowledges efforts to expedite reviews, but concludes they “not really playing out…on the private side” yet, and that the impact is more acute for public biotech. ³⁴ This supports the idea that even if FDA announces streamlining initiatives, execution and predictability have lagged.

Net effect on demand

The FDA challenge is portrayed less as a one-time policy change and more as a persistent uncertainty environment that can repeatedly disrupt planning assumptions—especially for tenants dependent on regulatory milestones to unlock financing and move into space-intensive stages. ¹³

---

3) “Behavioral” implications for tenant demand and leasing activity

A. Demand is constrained by financing realities for preclinical/clinic tenants

One excerpt states that on the public side, markets are open for “good data and key milestones,” but for “most public biotechs in preclinical or in the clinic, which don’t have data or milestones to finance off of,” it has been “a very tough slog.” ⁵ While this passage also discusses capital markets, it connects logically to the FDA/NIH issues because regulatory and funding uncertainty make it harder to reach or finance milestones.

B. A specific leasing signal: no public biotech leases in a quarter

Management says: “This is maybe the first quarter in the history of the company…where we didn’t sign a single public biotech lease,” explicitly attributing it to “a combination of a lot of factors,” including the broader environment they’ve been describing. ⁶ The earlier excerpts identify FDA and NIH as key “pinch points.” ¹

C. Private demand may be more resilient, but confidence still depends on regulation/budget

Management indicates that private ventures continue to raise and deploy money but in a “more judicious fashion,” and that FDA impact is “really more impactful on the public markets,” though it still affects private markets “in the sense of confidence in raising the money.” ⁴ This suggests FDA leadership uncertainty can suppress demand indirectly through fundraising and risk appetite, even if private capital is more willing to deploy under some conditions.

---

4) Summary: how FDA leadership + NIH budget issues translate into demand headwinds

Putting the excerpts together, the current demand headwinds in life science space appear to stem from:

1. NIH turmoil and reimbursement/budget pressure

   • Indirect cost reimbursement limitations disrupted markets and paused demand, with “NIH 15%” described as halting “almost all demand” in the Boston area and beyond, with policy reversal still taking time to work through. ¹²

2. FDA leadership uncertainty and recurrent regulatory shocks

   • FDA is described as a “huge problem” with frequent negative releases creating “shock effect,” raising uncertainty around approvability and forcing companies to constantly manage time and cost. ¹

3. Resulting operational/expansion caution

   • Public biotech leasing is described as particularly weak (e.g., no public biotech leases in the quarter), consistent with a broader environment where milestones, timelines, and financing conditions are strained by regulatory and funding uncertainty. ⁶⁵

4. A broader “slower play” dynamic

   • Management indicates that while there are hopeful elements (e.g., easing on NIH-related issues after reimbursement limitations), leadership remains a problem and the overall environment remains challenging, implying continued caution until stability improves. ¹⁷²

---

Bottom line

The excerpts portray FDA leadership and regulatory uncertainty as a continual source of disruption (“shock effect”) that increases regulatory risk and stretches the time/cost/approvability calculus for tenants, while NIH budget and reimbursement issues create funding and institutional-cost uncertainty that can pause demand—especially for early-stage research and institution-linked leasing. ¹³⁵²